

New Drug Approvals

Generic Name (Trade Name—Company)

July 1, 2011

Uses/Notes

Prophylaxis of deep vein thrombosis (DVT) that may lead to pulmonary embolism (PE) in patients undergoing knee or hip replacement surgery

Rivaroxaban

(Xarelto—Bayer, Janssen Pharmaceuticals)

First oral factor Xa inhibitor approved for DVT prophylaxis

This novel oral anticoagulant is a factor Xa inhibitor that is dosed as 10 mg once daily for 35 days following hip replacement surgery and for 12 days following knee replacement surgery. According to a company [press release](#), approval was based on results from the RECORD 1, 2, and 3 studies, which compared rivaroxaban 10 mg/d with enoxaparin 40 mg/d for DVT prophylaxis following knee or hip replacement surgery. In all studies, use of rivaroxaban was associated with significantly fewer venous thromboembolic events compared with enoxaparin (*P*

Source URL:

<http://aphanet.org/first-oral-factor-xa-inhibitor-approved-dvt-prophylaxis>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.